Lateral Flow Assay Device for Rapid Diagnostic of Cutaneous Leishmaniasis (LAFALE [lateral flow assay for leishmaniasis] platform)
LAFALE is based on an immune-chromatographic assay where antibodies bind to synthetic peptides opH2A and opLiP2a immobilized on a membrane strip. As the serum flows through the membrane, the antibodies against antigens of Leishmania interact with the peptides and due to gold nanoparticle conjugate a positive interaction yields a red color in the test line. LAFALE platform will offer a rapid detection of cutaneous leishmaniasis (CL) within 30 minutes, a suitable time for Point of Care (POC) diagnosis. Worldwide CL distribution offers the possibility of an international market.
Patents: Germany, Colombia, Spain, United States, France, Malaysia, European Patent Office (EPO), Peru, United Kingdom.
Patents in process in Brazil and India.